News & Updates

The updated efficacy analysis of the phase III MARIPOSA trial continues to favour amivantamab plus lazertinib over osimertinib for first-line (1L) treatment of patients with EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).

In a preplanned interim analysis of the NIAGARA trial, the addition of durvalumab to neoadjuvant chemotherapy prior to radical cystectomy (RC) and durvalumab monotherapy following surgery confers a survival advantage over chemo alone for muscle-invasive bladder cancer (MIBC).

Results from the phase III KEYNOTE-522 study presented at ESMO 2024 show a statistically significant and clinically meaningful improvement in overall survival (OS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemo alone for previously untreated, high-risk, early-stage triple-negative breast cancer (TNBC).

In the management of severe cancer pain, intravenous patient-controlled analgesia (PCA) with hydromorphone delivers superior pain control with greater patient satisfaction as compared with conventional oral morphine, according to the phase III open-label SYLT-021 study.

First-line cemiplimab monotherapy continues to provide durable overall (OS) and progression-free survival (PFS) benefits at 5 years compared with chemotherapy in advanced nonsmall cell lung cancer (NSCLC) patients with PD-L1 expression ≥50 percent, according to the results of the EMPOWER-Lung 1 study presented at WCLC 2024.